Emerging Concepts in Chronic Kidney Disease Management: How to utilize innovative approaches to improve outcome of Chronic Kidney Disease Patients

Optimal Chronic Kidney Disease Management:
How to care for the patient trajectory?
Professor Kai-Uwe Eckardt (Germany)

Techniques and Practices in Renal Replacement Therapy:
How to match solutions to the problems?
Professor Christopher McIntyre (Canada)

Dialysis Intelligence:
How can measuring, analyzing and reporting data improve patient outcomes?
Professor Bernard Canaud (Germany/France)

Improving outcomes along the complex CKD patient pathway.

At the 52nd ERA-EDTA Congress,
London, UK
May 29, 2015
Time: 13:30–15:00 hrs
Venue: ExCeL London, N10 - Level 1

Chairmen:
Professors Carlo Gaillard (The Netherlands) and Jürgen Floege (Germany)
Reaching new frontiers in the clinical management of ADPKD

Bringing together experience to discuss the burden of ADPKD, review pivotal data supporting emerging treatments use and provide expert opinion on considerations for the clinical management of the disease.

Friday 29 May, 13.30–15.00
Room N11, ExCeL

Chair: Prof Vicente Torres
(Mayo Clinic College of Medicine, USA)

Programme and speakers:
ADPKD: Overview of the disease and clinical management strategies
Prof Henrik Birn
(Aarhus University Hospital, Denmark)

Emerging treatment of ADPKD – a review of the data
Prof Vicente Torres

Clinical considerations for future management
Prof Ron Gansevoort
(University Medical Centre Groningen, Netherlands)

Followed by a Q&A session

Lunch bags will be provided at the start of the symposium
Lunchtime Symposium

Friday 29 May 2015
13.30–15.00
S11, ExCeL
London Exhibition and Convention Centre
London, UK

High-dose Haemodialysis – Enhancing the Provider and Patient Experience

With a distinguished international faculty, chaired by Sandip Mitra, this symposium will focus on the clinical and economic evidence for high-dose haemodialysis delivered at home compared with conventional or in-centre haemodialysis, and includes a patient’s own experience of the practical, emotional and health-related aspects of this therapy. This stimulating and informative educational meeting has been designed to support healthcare providers within different healthcare systems, focusing on evidence-based clinical guidance as well as real-world practical advice on how to improve outcomes for long-term dialysis patients.

Programme

Chair’s Welcome and Introduction
Sandip Mitra, UK

Clinical Benefits of High-dose Haemodialysis
James Heaf, Denmark

Health Economic Advantages of High-dose Haemodialysis
Christopher Chan, Canada

A Patient Perspective
Madeleine Warren, UK

Summary and Closing Remarks
Sandip Mitra, UK

A boxed lunch will be served from 13.30
We look forward to seeing you there
52nd ERA-EDTA Congress 2015

Why, Who and How to Treat Iron Deficiency Beyond Anaemia in Patients with Chronic Kidney Disease

Friday 29 May 2015
13:30–15:00
Level 3, Capital Suite 14–16
ExCel London Exhibition and Convention Centre

PROGRAMME

13:30 Lunch boxes will be provided

13:45 Welcome and Introduction
Chair: David Goldsmith (London, UK)

13:55 Why to treat: the benefits of treating iron deficiency beyond anaemia
Stefan Anker (Göttingen, Germany)

14:10 Who to treat: identifying which patients benefit most from iron therapy
Simon Roger (Gosford, Australia)

14:25 How to treat: choosing the right iron formulation at the right dose for the right patient
Iain Macdougall (London, UK)

14:45 Q&A

Dear Colleague,

It gives me great pleasure to welcome you to the Vifor Fresenius Medical Care Renal Pharma-sponsored symposium, entitled ‘Why, who and how to treat iron deficiency beyond anaemia in patients with chronic kidney disease’.

During today’s educational programme I will be joined by an internationally renowned faculty who will first provide an overview of the clinical benefits of treating iron deficiency, discussing what these benefits may mean for patients with chronic kidney disease (CKD). We will then consider which patients would benefit most from iron therapy, with a particular aim of shifting physicians’ minds from only treating anaemia towards also treating iron deficiency. Finally, we will discuss how to differentiate between available iron preparations in order to select a treatment that will achieve an effective, safe, controlled and predictable therapeutic outcome, primarily focusing on the clinical benefits that intravenous iron therapy can offer.

This promises to be an engaging and informative educational session. I encourage you to submit your questions for the Q&A session by completing the question cards provided and handing them to an organizer during the symposium.

Professor David Goldsmith

Vifor Fresenius Renal Medical Care has fully sponsored this symposium and worked with the speakers on choice of topic and content. Payment has been made to the Congress organizer to hold the symposium and lunch boxes have been provided by the company.
Iron Needs and Newer Modes of Delivery in Hemodialysis

Invitation to a CME Symposium at the ERA-EDTA 2015 Congress in London

Friday, May 29, 2015, 13.30–15.00
Capital Suite 7-12 · Level 3

Target Audience
This activity has been designed to meet the educational needs of Nephrology professionals involved in the care of patients with kidney disease.

Purpose of Activity
Two major therapeutic areas facing nephrologists as part of their dialysis care are anemia and bone mineral disorders. This symposium will provide increased understanding of current practices in the replacement of iron and in the calcium-free management of hyperphosphatemia. The focus will be on the dual role of iron-based phosphate binders.

Educational Objectives
After completing this activity, the participant should be better able to:
1. Review the conditions that lead to iron replacement needs in patients on hemodialysis.
2. Discuss the modes, risks and limitations of current iron replacement strategies.
3. Explain newer methods to replace iron losses in hemodialysis patients.

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of SynAptiv and The Med Ed Group. SynAptiv is accredited by the ACCME to provide continuing medical education for physicians. SynAptiv designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There is no fee for this educational activity.
Industry Symposia Booklet

Alexion Satellite Symposium at the 52nd Annual Scientific Meeting of the European Renal Association & European Dialysis and Transplant Association

Thrombotic microangiopathy (TMA) is a serious disease that can result in severe, irreversible organ damage, and considerable morbidity and mortality. TMA has several causes, including atypical Haemolytic Uraemic Syndrome (aHUS) and thrombotic thrombocytopenic purpura. This symposium will provide you with up-to-date information about the therapeutic management of patients with aHUS, describing the current challenges in rapid differential diagnosis and monitoring disease progression. We will also provide hands-on practical advice from both laboratory and clinician’s perspectives.

A lunch will be served at the symposium.

You are invited to attend

How to diagnose and how to treat aHUS today

Friday 29 May 2015, 13:30-15:00
Capital Suite 8-9 - Level 3, ExCel London

Chair: Dr Paul Warwicker, Clinical Director, Lister Renal Units, Stevenage, Hertfordshire, UK

Programme

From bench to bedside in aHUS: Historical perspectives
Paul Warwicker
United Kingdom

How to diagnose and monitor aHUS: Laboratory perspectives
Marina Noris
Italy

Which clinical evaluations and when?
Nils Heyne
Germany

aHUS, CKD and beyond: how to treat to avoid the irreparable
Ondrej Viklicky
Czech Republic

Please visit the Alexion booth in the exhibition hall

Prescribing Information is available at the Booth and Meeting

Information presented at this Industry-sponsored symposium is not necessarily endorsed by ERA-EDTA
of cystinosis patients are adults

Living with Cystinosis Survey results, Jan. 2011

Industry Symposia Booklet

Industry Symposia Booklet

Cystinosis – evolution from paediatric to adult disease

Join us for a lunch symposium at the 52nd ERA-EDTA Congress

Friday, May 29th, 2015
13:30 – 15:00
Capital Suite 2-3-4 (Level 3)
ExCeL CONGRESS CENTRE
LONDON

Chair:
Christoph Wanner, Würzburg, Germany

13:30
Chairman’s welcome
Christoph Wanner

13:40
Cystinosis overview
Elena Levchenko, Leuven, Belgium

14:00
Extra-renal manifestations in cystinosis
Graham Lipkin, Birmingham, UK

14:20
Adolescent to adult: Transition, transplant, treatment
Aude Servais, Paris, France

14:40
Discussion
Christoph Wanner

14:55
Closing remarks
Christoph Wanner

Lunch boxes will be provided
Novel iron-containing phosphate binder
The value added

Saturday, May 30th 2015
13:30 – 15:00 hrs
ExCeL N10

Chairs: John Cunningham (UK), Jordi Bover (ESP)

- Why was it necessary to invent sucroferric oxyhydroxide?
  David Goldsmith (UK)

- Phosphate binding is the name of the game – playing strong in the CKD MBD field
  Jürgen Floege (GER)

- Dialysis patients in focus – Potential added benefits
  Stuart Sprague (USA)

Please also visit us at the Vifor Fresenius Medical Care Renal Pharma booth
Lunchtime Symposium
Saturday 30 May 2015, 13.30–15.00
N11, ExCeL London Exhibition and Convention Centre

Optimising the Haemodialysis Patient Journey

A distinguished international faculty, chaired by Vladimir Tesar, will examine the optimal management of in-centre haemodialysis patients and review the evidence around unmet clinical needs as well as the benefits of an individualised approach to care. The symposium will cover key elements of optimised patient care, including recent advances in dialysis membrane technology and management of cardiac problems in haemodialysis patients. This stimulating and informative educational meeting has been designed to support healthcare professionals to make clinically relevant changes in their practice, by providing practical advice on how to improve outcomes along the haemodialysis patient journey.

Programme

Chair’s Welcome and Introduction
Vladimir Tesar, Czech Republic

Optimising In-centre Haemodialysis Care – a Wider Perspective
Mohamed Hani Hafez, Egypt

Different Membranes to meet Diverse Needs
Alexander Rosenkranz, Austria

Preventing Short- and Long-term Cardiac Problems in Haemodialysis
Nick Selby, UK

Summary and Closing Remarks
Vladimir Tesar, Czech Republic

A boxed lunch will be served from 13.30
We look forward to seeing you there
Identifying ADPKD patients with evidence of rapidly progressing disease

Bringing together experience and opinion to discuss the currently unmet need in the clinical community for practical and informative guidance on the identification of high-risk patients in ADPKD.

**Saturday 30 May, 13.30–15.00**
Room S11, ExCeL

**Chair:** Prof Bertrand Knebelmann
(Hôpital Necker-Enfants Malades, Paris)

**Programme and speakers:**
- Defining and predicting rapid progression
  Prof Yannick Le Meur
  (CHU La Cavale Blanche, Brest)
- The value of prediction
  Prof Arlene Chapman
  (The University of Chicago Department of Medicine, USA)
- Moving towards consensus
  Prof Bertrand Knebelmann

Lunch bags will be provided at the start of the symposium

Followed by a Q&A session
Progressing IV iron treatment for non-dialysis CKD patients – NEW comparative clinical data

Pharmacosmos Symposium at the 52nd ERA-EDTA Congress, London 2015

Date: Saturday 30th May 2015
Time: 13:30–14:45
Venue: Capital Suite 14-15-16

Programme

<table>
<thead>
<tr>
<th>Event</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman’s welcome</td>
<td>Andrzej Więcek</td>
<td>Poland</td>
</tr>
<tr>
<td>The PROGRESS study – a randomised, controlled trial comparing iron isomaltoside 1000 to oral iron for iron deficiency anaemia in non-dialysis CKD</td>
<td>Philip Kalra</td>
<td>UK</td>
</tr>
<tr>
<td>The WAVE study – a large prospective observational study of iron isomaltoside 1000 treatment for iron deficiency anaemia in CKD</td>
<td>Frank Leistikow</td>
<td>Germany</td>
</tr>
<tr>
<td>Optimal iron management in non-dialysis CKD – putting it all together</td>
<td>Saeed Ahmed</td>
<td>UK</td>
</tr>
<tr>
<td>Conclusion and questions</td>
<td>Led by Chairman</td>
<td></td>
</tr>
</tbody>
</table>

Pharmacosmos develops and markets medicines for the treatment of iron deficiency. A research-based company, its ongoing R&D programme focuses on improving the treatment options with maximum efficacy, convenience and safety for patients and professionals.
Dimensions of fluid management in renal replacement therapy

Program and speakers:

- **Hypotensive episodes in dialysis need attention**
  Prof. Antonio Santoro, Bologna, IT

- **Biomarkers and optimal CRRT treatment in AKI – the nephrology view**
  Prof. Andreas Kribben, Essen, GER

- **Convection volumes in HDF – the KUF max concept**
  Dr. Angel Argiles, Montpellier, FR

**Chair:** Prof. Johannes Mann, GER

Saturday, May 30, 13:30–15:00h, ROOM: Capital Suite 7–12
In hemodialysis therapy, blood cells such as white blood cells and platelets are activated by the physical contact with dialysis membrane or the components of dialysate and so on. Activated platelets play the important roles as potent inflammatory cells on several pathogenesis.

In this symposium, we focus on activated platelets during hemodialysis and present an overview of the interactions of activated platelets of dialysis patients, and furthermore introduce the possible clinical effects produced by suppression of platelet activation based on three randomized controlled trials with anti-thrombogenic membrane.

Mr. Ueno, a polymer scientist, introduces the technical aspects of a novel anti-thrombogenic membrane developed by the attention to the adsorbed water on the membrane surface. Because of its suppression property for inflammation, Dr. Kakuta obtained the results of significantly reduced amount of ESA through 6 months usage of anti-thrombogenic membrane, in “TOKAI cytokine removal study”. Dr. Tsuchida has proved the significant improvement of intradialytic hypotension in diabetic hemodialysis patients with new membrane, called “ATHRITE-BP” study. Finally Dr. Brendolan tried to demonstrate the direct effect of suppressing the platelet activation with a new membrane in vitro and “TRIATHRON” study.
We invite you to attend and solve the mysteries of hyperkalemia during this exciting educational program.

SATURDAY, MAY 30, 2015
13.30 to 15.00
Capital Suite 8-9
Lunch will be provided.

Planned and developed by Medavera, Inc. and supported by an educational grant from ZS Pharma, Inc.
INVITATION TO THE GENZYME LUNCH SYMPOSIUM

ER A-EDTA Genzyme Sponsored Satellite Symposium
SATURDAY, 30.05.2015 | 13:30 - 15:00 HRS | CAPITAL SUITE 2-3-4 (LEVEL 3)
Come visit our booth D90

STEPS FORWARD: FABRY DISEASE IN NEPHROLOGY

Professor Alberto Ortiz (Spain) - CHAIR
Chief of Nephrology at IIS-Fundacion Jimenez Diaz, Madrid and Professor of Medicine and Vice-Dean for Research at the Medical School of University Autonoma of Madrid.
Occurrence of Severe Clinical Events by time on Agalsidase Beta among Patients with Fabry Disease

Doctor Renzo Mignani (Italy)
Chief of Ambulatory Renal Transplant and Chief of Rare Disease Nephrology Department at Rimini Hospital (Italy)
FABry STabilization indEX (FASTEX)

Professor Dominique P. Germain (France)
Professor of Medical Genetics at the University of Versailles, the Director of the Research Unit ‘Biotherapies of Fabry disease’ within the Unité Mixte de Recherche, Université de Versailles / INSERM (Health and Medical Research National Institute), head of the Division of Medical Genetics of the Paediatric Department at the Raymond Poincaré Hospital and the Referral Center for Fabry disease in Garches
Ten-year outcome of Enzyme Replacement Therapy with Agalsidase Beta in Patients with Fabry Disease

This meeting is Sponsored by Genzyme, a Sanofi Company. All speakers at this meeting are expressing their personal opinion and these are not necessarily those of Genzyme.

Lunch will be provided
PLEASE JOIN US FOR THE ABBVIE-SPONSORED SYMPOSIUM AT THE 52ND ERA-EDTA CONGRESS

DIABETIC NEPHROPATHY 2020
Saturday, 30 May 2015 | 13.30 – 15.00
Capital Suite 17 | Convention Center | London, England

AGENDA
What is Missing from Our Understanding of Diabetic Nephropathy Chronic Kidney Disease (DN-CKD)?
What Do the Previous Trials Tell Us?

Bruce Hendry
(United Kingdom)

Can We Identify the Patient at Risk of Rapid Progression?

Adeera Levin
(Canada)

Can We Identify the Effect of Therapy in type 2 Diabetic Patients with Renal Impairment?

Dick de Zeeuw
(Netherlands)

Lunch will be provided

LEARNING OBJECTIVES:
• To provide information to nephrologists regarding the scope of diabetic nephropathy and healthcare implications
• To understand limitations of current therapies and why effective therapies are needed
• To understand the lesson learned from past trials to prevent progression to ESRD and understand what future and ongoing research may bring
• To educate on how to identify type 2 diabetes patients at risk for progression to ESRD and how to evaluate treatment effect
Lunchtime Symposium
Sunday 31 May 2015, 12.15–13.15
Capital Suite 2-3-4, ExCeL
London Exhibition and Convention Centre, London, UK

Supporting CKD Patients at Home

This symposium will be led by a distinguished international faculty, chaired by James Heaf, who will examine evidence around unmet clinical needs in patients with chronic kidney disease and the potential benefits of remote clinical monitoring of patients on dialysis. The faculty will focus on the lessons learnt from the management of patients with cardiac disease, and how this evidence may help in meeting the specific challenges of dialysis patient care. This stimulating and informative educational meeting has been designed to support a range of healthcare professionals in understanding and applying innovative solutions to support and monitor patients receiving treatment at home.

Programme

Chair’s Welcome and Introduction
James Heaf, Denmark

Learning from Others – the Benefits of Remote Monitoring in Cardiac Care
Martin Cowie, UK

Remote Monitoring to Support CKD Patients – What are the Needs?
Manuel Pestana, Portugal

Summary and Closing Remarks
James Heaf, Denmark
The Gambro AK 98 system aims to enhance your dialysis treatments and may help you balance your clinical targets and operational objectives.

**TOUCH SCREEN**
A new user-friendly touch screen designed to improve ease of use and efficiency for each and every dialysis session.

**DIASCAN**
The DIASCAN function provides real-time monitoring of dialysis efficiency allowing you to reach your treatment targets.

**ALARMS**
External alarms allow you to always keep warnings in sight.

**TIME BETWEEN TREATMENT**
Improved preparation & disinfection aims to decrease time between treatments.

See the AK 98 system live at Booth A40-B50